Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;17(1):14-29.
doi: 10.2174/0118744710262369231110065230.

Ferroptosis Inducers as Promising Radiosensitizer Agents in Cancer Radiotherapy

Affiliations
Free article
Review

Ferroptosis Inducers as Promising Radiosensitizer Agents in Cancer Radiotherapy

Fatemeh-Jalali Zefrei et al. Curr Radiopharm. 2024.
Free article

Abstract

Radiotherapy (RT) failure has historically been mostly attributed to radioresistance. Ferroptosis is a type of controlled cell death that depends on iron and is caused by polyunsaturated fatty acid peroxidative damage. Utilizing a ferroptosis inducer may be a successful tactic for preventing tumor growth and radiotherapy-induced cell death. A regulated form of cell death known as ferroptosis is caused by the peroxidation of phospholipids containing polyunsaturated fatty acids in an iron-dependent manner (PUFA-PLs). The ferroptosis pathway has a number of important regulators. By regulating the formation of PUFA-PLs, the important lipid metabolism enzyme ACSL4 promotes ferroptosis, whereas SLC7A11 and (glutathione peroxidase 4) GPX4 prevent ferroptosis. In addition to introducing the ferroptosis inducer chemicals that have recently been demonstrated to have a radiosensitizer effect, this review highlights the function and methods by which ferroptosis contributes to RT-induced cell death and tumor suppression in vitro and in vivo.

Keywords: Ferroptosis; cancer; cell death.; radioresistance; radiosensitizer; radiotherapy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Gong L.; Zhang Y.; Liu C.; Zhang M.; Han S.; Application of radiosensitizers in cancer radiotherapy. Int J Nanomedicine 2021,16,1083-1102 - DOI - PubMed
    1. Kim W.; Lee S.; Seo D.; Kim D.; Kim K.; Kim E.; Kang J.; Seong K.M.; Youn H.; Youn B.; Cellular stress responses in radiotherapy. Cells 2019,8(9),1105 - DOI - PubMed
    1. Wang D.; Progress in the study of ferroptosis in cancer treatment: State-of-the-Art. Chem Biol Interact 2023,371,110348 - DOI - PubMed
    1. Franzone P.; Fiorentino A.; Barra S.; Cante D.; Masini L.; Cazzulo E.; Todisco L.; Gabriele P.; Garibaldi E.; Merlotti A.; Redda M.G.R.; Alongi F.; Corvò R.; Image-guided radiation therapy (IGRT): practical recommendations of Italian Association of Radiation Oncology (AIRO). Radiol Med (Torino) 2016,121(12),958-965 - DOI - PubMed
    1. Farhood B.; Goradel N.H.; Mortezaee K.; Khanlarkhani N.; Salehi E.; Nashtaei M.S.; Mirtavoos-mahyari H.; Motevaseli E.; Shabeeb D.; Musa A.E.; Najafi M.; Melatonin as an adjuvant in radiotherapy for radioprotection and radiosensitization. Clin Transl Oncol 2019,21(3),268-279 - DOI - PubMed

MeSH terms

Substances